Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO WCGIC 2020 | DELIVER: nivolumab in advanced gastric cancer

Yu Sunakawa • 28 Jun 2020
ESMO WCGIC 2020
Gastric Cancer Gastrointestinal Cancer Antibodies Nivolumab
DELIVER

Yu Sunakawa, MD, PhD, of St. Marianna University School of Medicine, Kawasaki, Japan, outlines an updated analysis of the DELIVER trial (JACCRO GC-08), evaluating nivolumab in advanced gastric cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Yu Sunakawa

3:15
Predictive biomarkers for RAS-wt mCRC treated with cetuximab and m-FOLFOXIRI
Yu Sunakawa • 21 Oct 2023
3:01
DEEPER: m-FOLFOXIRI and cetuximab versus bevacizumab in mCRC
Yu Sunakawa • 20 Jan 2023
2:36
Real-world use of nivolumab in gastric cancer
Yu Sunakawa • 8 Jun 2021
2:45
1L FOLFOXIRI plus cetuximab or bevacizumab for RAS wild-type mCRC
Yu Sunakawa • 8 Jun 2021

Related Videos

1:53
Important pathophysiological determinants of elevated cirDNA post-surgery
Alain Thierry • 9 Apr 2024
0:47
Emerging molecular drivers and biomarker targets in gastroesophageal cancers
Tatsuhiro Shibata • 9 Apr 2024
0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals